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ZRANB3 is an African-speciﬁc type 2 diabetes locus
associated with beta-cell mass and insulin
response
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Genome analysis of diverse human populations has contributed to the identiﬁcation of novel
genomic loci for diseases of major clinical and public health impact. Here, we report a
genome-wide analysis of type 2 diabetes (T2D) in sub-Saharan Africans, an understudied
ancestral group. We analyze ~18 million autosomal SNPs in 5,231 individuals from Nigeria,
Ghana and Kenya. We identify a previously-unreported genome-wide signiﬁcant locus:
ZRANB3 (Zinc Finger RANBP2-Type Containing 3, lead SNP p= 2.831 × 10−9). Knockdown or
genomic knockout of the zebraﬁsh ortholog results in reduction in pancreatic β-cell number
which we demonstrate to be due to increased apoptosis in islets. siRNA transfection of
murine Zranb3 in MIN6 β-cells results in impaired insulin secretion in response to high
glucose, implicating Zranb3 in β-cell functional response to high glucose conditions. We also
show transferability in our study of 32 established T2D loci. Our ﬁndings advance under-
standing of the genetics of T2D in non-European ancestry populations.
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The genetic architecture of type 2 diabetes (T2D,MIM:125853) in Africa remains largely understudied.While the reduced linkage disequilibrium (LD) character-
istic of African populations was used to reﬁne and ﬁne map the
original TCF7L2 genetic association1,2, genome-wide and/or high
throughput studies of the genetics of T2D in Africa remain
limited to a genome-wide linkage analysis3, and a large-scale
replication study4, both from the Africa America Diabetes Mel-
litus (AADM) Study. African American populations, on the other
hand, have been studied more comprehensively including several
genome-wide association studies (GWAS) and meta-analysis of
GWAS5. However, African American populations should not be
used as proxies for populations in Africa because of differences in
genetic (African Americans have ~20% European admixture) as
well as nongenetic risk factors (including lifestyle and behavioral
factors). Therefore, despite the advances over the last decade in
our understanding of the role of genetic variants inﬂuencing T2D
risk and the identiﬁcation of the role of the genes in pathophy-
siology, data from Africa remains scarce.
In the present study, we conduct a GWAS of T2D in Africa
using data from over 5,000 Africans enrolled from Nigeria,
Ghana, and Kenya as part of the Africa America Diabetes Mel-
litus (AADM) study3,6, and extend the transferability of pre-
viously reported T2D loci in Africa. We identify a novel genome-
wide signiﬁcant locus for T2D—the Zinc Finger RANBP2-Type
Containing 3 (ZRANB3) gene. Functional studies of the ZRANB3
ortholog in zebraﬁsh show that either genomic knockout or
antisense knockdown of the gene leads to reduction in β-cell
number in the developing embryo which we demonstrate to be
due to a reproducible increase in apoptosis in islets. Notably,
Zranb3 knockdown in cultured MIN6 β-cells results in impaired
secretion of insulin in response to high glucose. Our ﬁndings
represent an advance in our knowledge of the genetics of T2D in
sub-Saharan Africa.
Results
Characteristics of discovery sample. The characteristics of the
5231 AADM study participants (2342 T2D cases and 2889 con-
trols) are shown in Supplementary Table 1. T2D cases were older
than controls (mean age 55 years versus 46 years). Mean body
mass index (BMI) was similar between cases and controls. How-
ever, cases had a signiﬁcantly bigger waist circumference than
controls (mean 93.7 cm versus 88.5 cm). Fasting glucose values
indicate that most of the T2D patients had not achieved glycemic
control at the time of enrollment with a median fasting glucose of
153mg/dl (8.5 mmol/L) and more than three-quarters of the
participants having fasting glucose values greater than 109mg/dl
(6.1 mmol/L) at the time of enrollment into the study. PC plots of
the genotypes showed clustering of the study participants by
geography and ethnolinguistic group (Supplementary Fig. 1).
Discovery genetic association analysis. The distribution of
association statistics for the genome-wide association analysis is
shown in the Manhattan plot (Fig. 1). There was minimal inﬂa-
tion of the association statistics (λ= 1.013, Supplementary Fig. 2).
Analysis with or without BMI in the association model yielded
essentially the same ﬁndings. Three genome-wide signiﬁcant loci
were identiﬁed (Table 1): TCF7L2 (lead single-nucleotide poly-
morphism (SNP) rs7903146, T allele frequency= 0.331, p=
7.288 × 10−13, score test), HMGA2 (lead marker rs138066904,
deletion frequency= 0.096, p= 2.516 × 10−9, score test) and
ZRANB3—Zinc Finger RANBP2-Type Containing 3 (lead SNP
chr2:136064024, T allele frequency= 0.034, p= 2.831 × 10−9,
score test). TCF7L2 is an established T2D risk locus and the lead
SNP of TCF7L2 (rs7903146) in the present study is the same lead
SNP reported in most GWAS of T2D to date (Fig. 2). HMGA2 is
also a known T2D locus in both Europeans and African Amer-
icans. However, the genome-wide signiﬁcant HMGA2 variant in
the present study is a deletion (CCTAG/C), not a SNP like other
HMGA2 markers that have previously been found to be genome-
wide signiﬁcant for T2D in Europeans (leading SNP rs2258238,
68.5 kb away from the deletion) and in African Americans
(leading SNP rs343092, 38.6 kb away). The LD between the
deletion and these other SNPs is low (r2 0.052 and 0.003,
respectively) in this study of sub-Saharan Africans.
Replication and annotation of ZRANB3. The association ﬁnd-
ings implicate ZRANB3 as a candidate locus for T2D as it has not
been previously reported in relation to T2D. The two genome-
wide signiﬁcant SNPs have a frequency of 3.6% and 6.9%,
respectively (Table 2) and the r2 between them is 0.66. They both
appear to be African-speciﬁc as they are not present in other
populations as evaluated through the 1000 Genomes and gNO-
MAD databases. For evaluation of replication of ZRANB3 in
another African ancestry population, we examined these variants
in South African Zulu T2D cases and controls from the Durban
Diabetes Case–Control Study (DCC) and the Durban Diabetes
Study (DDS)—Table 2. The leading SNPs in ZRANB3 in AADM
each showed consistency of direction of effect in the Zulu GWAS,
despite the latter study showing lower effect allele frequencies
(chr2:136064024: T allele frequency 0.9% Zulu versus 3.4%
AADM; rs1465146591 (chr2:136019729) A allele frequency 2.6%
Zulu versus 6.9% in AADM). Although these ﬁndings did not
reach nominal signiﬁcance, the combined p values for the two
leading SNPs across the discovery and replication samples
remained genome-wide signiﬁcant (Table 2).
ZRANB3 is a protein-coding gene with nucleic acid binding
and endonuclease activity. The ZRANB3 transcript is the target of
nonsense-mediated decay (NMD) and is expressed in tissues
relevant to T2D, including adipose tissue, skeletal muscle,
pancreas, and liver (Supplementary Fig. 3). We identiﬁed
haplotype blocks around the two genome-wide signiﬁcant
ZRANB3 SNPs and identiﬁed 35 and 43 target genes, respectively,
from the signiﬁcant trans-eQTL-gene associations in each
haplotype block using the Framingham Heart Study (FHS) eQTL
database (Supplementary Table 2). We also identiﬁed ﬁve
common target genes for cis-expression quantitative trait loci
(eQTLs) in addition to ZRANB3. Overlaying these associations
with known T2D loci from the GWAS Catalog highlighted two
known-T2D genes associated with cis-eQTLs (MCM6, DARS) and
four with trans-eQTLs (DGKB, GTF3AP5-AGMO, IL23R/
IL12RB2, SLC44A4). It is noteworthy that there is a ClinVar
record of a duplication in ZRANB3 associated with gestational
diabetes (ClinVar Accession SCV000191187.1: see Web
Resources). Also, data from the Rat Genome Database shows
that the syntenic region contains QTLs for insulin levels (insulin
level quantitative trait locus (QTL) 44) and glucose level (glucose
level QTLs 66 and 67) in the rat. As of October 2018, there is no
ZRANB3 variant in the NHGRI-EBI GWAS Catalog or in OMIM
Replication of known T2D loci. We investigated the transfer-
ability of previously reported T2D SNPs in the AADM sample. Of
the 130 SNPs, 108 were present in our dataset. Sixteen SNPs (or
15%) showed exact replication, i.e., consistent direction of effect
for the alleles and p < 0.05—Table 3. Two other SNPs [rs2258238
(HMGA2) and rs12595616 (PRC1)] showed a p < 0.05 with
inconsistent direction of effect. Sixteen other loci showed local
replication, including KCNJ11, HHEX/IDE, THADA, MC4R, and
ATP8B2 (Supplementary Table 3). Of the two loci ﬁrst reported
in an African ancestry GWAS meta-analysis for T2D (the
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MEDIA Consortium), we found exact replication for INS-IGF2
rs3842770 (p= 1.867 × 10−2, Table 3), but no evidence for
replication for HLA-B rs2244020 (rs74995800, p= 0.798).
Meta-analysis and transethnic meta-analysis. We conducted an
African ancestry T2D meta-analysis that included this GWAS
and an African American meta GWAS7 consisting of ﬁve studies
(n= 8599); the Atherosclerosis Risk in Communities (ARIC), the
Cleveland Family Study (CFS), the Howard University Family
Study (HUFS), Jackson Heart Study (JHS), and Multi-Ethnic
Study of Atherosclerosis (MESA). This African ancestry meta-
analysis revealed four genome-wide signiﬁcant loci (Supplementary
Fig. 4, Supplementary Table 4), namely TCF7L2 (lead SNP
rs386418874 p= 6.33 × 10−11), TH-INS (lead SNP rs4072825 p=
2.35 × 10−8), KCNQ3 (lead SNP rs111248619 p= 2.71 × 10−8), and
an intergenic locus (lead SNP rs4532315 p= 9.80 × 10−9). TCF7L2
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Fig. 1 Manhattan plot of discovery GWAS: the AADM study
Table 1 SNPs most signiﬁcantly associated with T2D in 5231 sub-Saharan Africans (the AADM study)
CHR BP SNP Gene NEA EA EA freq. Score statistic Variance P value
10 114758349 rs7903146 TCF7L2 C T 0.331 146.777 418.603 7.288e−13
10 114754071 rs34872471 TCF7L2 T C 0.391 129.338 449.438 1.055e−09
10 114754784 rs35198068 TCF7L2 T C 0.390 128.338 448.171 1.342e−09
12 66289518 rs138066904 HMGA2 CCTAG C 0.096 72.999 149.997 2.516e−09
2 136064024 2:136064024 ZRANB3 A T 0.036 −39.914 45.135 2.831e−09
2 136019729 rs1465146591 ZRANB3 C A 0.069 −51.974 79.670 5.783e−09
10 114754088 rs7901695 TCF7L2 T C 0.504 125.252 473.671 8.664e−09
10 114756041 rs4506565 TCF7L2 A T 0.502 120.971 473.349 2.695e−08
10 114747860 rs386418874 TCF7L2 C CGT 0.238 96.130 321.980 8.449e−08
10 114754601 rs59326375 TCF7L2 G A 0.223 96.808 330.571 1.012e−07
2 136226838 2:136226838 ZRANB3 C T 0.039 −36.964 48.694 1.176e−07
7 44062728 rs116050569 Intergenic T C 0.063 53.858 105.402 1.555e−07
10 114755496 rs4132115 TCF7L2 G T 0.222 94.370 326.884 1.793e−07
7 44071333 rs531496714 RASA4CP C T 0.067 53.800 106.545 1.866e−07
EA effect allele, NEA noneffect allele
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Fig. 2 Regional association plots for TCF7L2 and ZRANB3 in the AADM GWAS for T2D
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and TH-INS are well-known T2D loci and TH-INS has also been
reported to be associated with other forms of diabetes (maturity-
onset-diabetes of the young and transient neonatal diabetes) and
other metabolic phenotypes. KCNQ3 (potassium voltage-gated
channel subfamily Q member 3) encodes a potassium voltage-
gated channel which regulates neuronal excitability. Defects in the
gene are a cause of a form of neonatal epilepsy (benign familial
neonatal convulsions type 2 or BFNC2), but variants in the gene
have not been associated with T2D or other metabolic pheno-
types. The chromosome 5 intergenic locus with lead SNP
rs4532315 has not been shown to be associated with any phe-
notype so far.
Transethnic meta-analysis of the above African ancestry
studies with a large GWAS of European ancestry individuals
(the DIAGRAM meta-analysis of type 2 diabetes (T2D) based on
the GoT2D integrated haplotypes)8 revealed multiple genome-
wide signiﬁcant loci as expected, including TCF7L2, KCNQ1,
FTO, IDE, IGF2BP2, CDKAL1, and SLC30A8. However, they are
all known loci, and none is a novel locus for T2D.
Suppression of zebraﬁsh zranb3 results in reduced β-cell mass.
To examine a potential role for zranb3 in T2D etiology in vivo,
we carried out functional studies of the zebraﬁsh ortholog,
zranb3, at larval stages. We ﬁrst examined embryonic expression
of the gene by RNA-seq in pancreatic β-cells isolated by FACS
from 5 dpf (days postfertilization) wild-type larvae, a stage at
which the larval β-cells are responsive to glucose and other
nutrients and also exhibit calcium oscillations indicative of a
functioning islet9,10. In comparison to other known β-cell genes
which were highly expressed, we also detected expression of
zranb3 in β-cells by RNA-seq, a ﬁnding which we did not observe
for markers of other tissues including heart and bone (Supple-
mentary Fig. 5a). This ﬁnding was conﬁrmed by quantitative
polymerase chain reaction (qPCR) (Supplementary Fig. 5b).
Next, we examined a role for zranb3 in the production or
maintenance of β-cells. We targeted the gene in transgenic
zebraﬁsh larvae in which β-cells could be visualized and
quantiﬁed, Tg(insa:mCherry)11. The zebraﬁsh ortholog was
targeted by two approaches. We generated a model of genomic
disruption of zranb3 by CRISPR/Cas9-mediated targeting of exon
4 of zranb3. Tg(insa:mCherry) embryos co-injected with multiple
zranb3-targeted short guide RNAs (sgRNA) and Cas9 mRNA
were cultured until 5 dpf and β-cell numbers were quantiﬁed by
identifying locations of intracellular mCherry+. We observed a
signiﬁcant reduction in β-cell numbers in F0 animals injected
with sgRNA (28.5 compared with 33.5 in controls, p= 0.0006, t
test). To conﬁrm that these effects were due to heritable genomic
disruption of zranb3, we propagated progeny of sgRNA-injected
animals of either the Tg(insa:mCherry) or wild-type background
by out-crossing the F0 mutation-carrying ﬁsh with wild-type ﬁsh
to generate F1 heterozygous ﬁsh which we then in-crossed to
generate F2 homozygous mutants. In both lines, we identiﬁed ﬁsh
homozygous for a deletion and early stop codons (Fig. 3a, b). We
examined the F2 mutants in both lines for β-cell mass using either
visualization of mCherry in the transgenic line or immunostain-
ing for insulin in the wild-type line. We found that genomic
mutation of the zranb3 gene in zebraﬁsh larvae results in an
observable reduction in β-cells, identiﬁed as either transgenic ins:
mCherry expression or the area of insulin+ antibody staining
Table 2 Association tests for the ZRANB3 T2D locus in AADM discovery (n= 5231) and Zulu replication (n= 2578) studies
Marker EA/
NEA
AADM EAF AADM β (SE) AADM
p value
Zulu EAF Zulu β (SE) Zulu
p value
Meta-analysis
Z
Meta-analysis
p value
2:136064024 T/A 0.036 −0.884
(0.149)
2.83E−09 0.009 −0.157
(0.133)
2.38E−01 −5.541 3.015E−08
rs1465146591 A/C 0.069 −0.652
(0.112)
5.78E−09 0.026 −0.102
(0.058)
7.74E−02 −5.781 7.446E−09
EA effect allele, NEA noneffect allele
Table 3 Exact replication of established T2D loci in 5231 sub-Saharan Africans
SNP CHR BP EA NEA EAF β SE p Value Locus
rs7903146 10 114758349 T C 0.331 0.351 0.049 7.29E−13 TCF7L2
rs10998572 10 70859204 A C 0.055 −0.245 0.105 1.933E−02 VPS26A
rs231360 11 2692249 T C 0.620 0.145 0.048 2.378E−03 KCNQ1
rs441613 11 2910191 C T 0.605 0.115 0.047 1.451E−02 KCNQ1
rs2258238 12 66221060 T A 0.367 −0.101 0.048 3.738E−02 HMGA2
rs12595616 15 91563513 C T 0.852 −0.227 0.066 5.438E−04 PRC1
rs1558902 16 53803574 A T 0.050 0.245 0.105 1.973E−02 FTO
rs2925979 16 81534790 C T 0.676 −0.107 0.049 2.950E−02 CMIP
rs7224685 17 4014384 T G 0.435 0.147 0.046 1.402E−03 ZZEF1
rs13342692 17 6946287 C T 0.393 0.145 0.047 2.009E−03 SLC16A11/A13
rs7234111 18 7067652 C T 0.584 0.0948 0.047 4.433E−02 LAMA1
rs4402960 3 185511687 T G 0.570 0.116 0.047 1.369E−02 IGF2BP2
rs1182436 7 157027753 C T 0.326 0.104 0.050 3.779E−02 MNX1
rs3802177 8 118185025 A G 0.038 −0.311 0.118 8.654E−03 SLC30A8
rs10757282 9 22133984 C T 0.207 0.149 0.056 7.372E−03 CDKN2A/B
rs1575972 9 22301092 A T 0.320 −0.196 0.049 6.47E−05 DMRTA1
rs10758593 9 4292083 A G 0.512 0.117 0.046 1.126E−02 GLIS3
rs3842770 11 2178670 A G 0.291 0.124 0.053 1.867E−02 INS-IGF2
EA effect allele, NEAnoneffect allele
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(Fig. 3c, d). In F2 mutants (n= 3), we found a mean of 23.0
(SD= 1.63) β-cells compared to wild-type age-matched control
larvae (n= 15) in which we found a mean of 33.47 (SD= 0.87) β-
cells (t test with unequal variances p= 0.0057). This reﬂects a
mean reduction of 30% in F2-mutant β-cells compared with wild-
type age-matched control larvae. Notably, we did not ﬁnd
observable changes in the domain of glucagon expression,
detected by immunoﬂuorescent antibody staining (Fig. 3d). No
developmental or morphological defects were observed in the
mutant larvae at any of the experimental stages.
To validate these observations, we also injected transgenic one-
cell embryos with a morpholino (MO) designed to disrupt
splicing of the endogenous zranb3 transcript at exon 4. We ﬁrst
validated the efﬁcacy of the MO to signiﬁcantly suppress zranb3
mRNA expression without inducing off-target toxicity by
assessing transcript levels of endogenous zranb3 and by
examining the presence of a marker of MO-induced toxicity,
the delta113 isoform of p5312, respectively (Supplementary
Fig. 6A). We cultured injected embryos to 5 dpf and we quantiﬁed
β-cell number. Quantiﬁcation by counting of mCherry-expressing
cells in larvae with suppression of zranb3 expression identiﬁed a
signiﬁcant reduction of β-cells (26.8 β-cells per larva compared
with 33.3 in control larvae, p= 0.0001, t test; Fig. 4). Quantiﬁca-
tion of β-cells identiﬁed using epiﬂuorescence was conﬁrmed by
confocal microscopy and pseudocolor-coding of whole-mount
islets to resolve individual cells within the primary islet (Fig. 4c).
These ﬁndings were consistent with the observations in the
CRISPR/Cas9 targeted embryos, suggesting that MO-induced β-
cell phenotypes are likely due to disruption of zranb3 expression.
The MO-induced effect was directly relevant to knockdown as the
impact on β-cell number increased with increased MO dose
(Fig. 4f). No developmental morphological defects were observed
in the morphants at any dose and at all stages assayed
(Supplementary Fig. 6B). Importantly, zranb3 loss appeared to
speciﬁcally impact β-cells because we found no signiﬁcant change
in expression of glucagon (Fig. 4d, e). Moreover, we did not detect
differences in glucose uptake in peripheral tissues in these
animals as determined by treatment with ﬂuorescent 2-NBDG
and quantiﬁcation of retinal ﬂuorescence13 (Supplementary
Fig. 7).
To further characterize the role of zranb3 on β-cell numbers,
we examined both proliferation and apoptosis. We assessed
proliferation in zranb3-deﬁcient Tg(insa:mCherry) embryos
using FACS analyses and mCherry+ expression to identify β-
cells. Cell cycle analysis was completed using DNA content
quantiﬁcation. We found similar proportions of β-cells in G1, S,
and G2/M phases as compared to control β-cells, suggesting no
signiﬁcant change in proliferation of these cells (Supplementary
Fig. 8). We then asked whether the reduction in β-cell number
may be attributable to increased cell death in β-cells. To test this,
we used whole-mount immunostaining of zebraﬁsh larvae using
an antibody against activated caspase-3, a marker of apoptosis
which can be observed in zebraﬁsh larval β-cells11. Compared to
control larvae in which we found only 4% of larvae expressing
caspase-3 in mCherry-positive islets, we found caspase-3 co-
localization with mCherry in 44% of zranb3-depleted larvae
(Fig. 5, p < 0.0001, chi-square test), consistent with an increase in
islet apoptosis accompanying knockdown of zranb3.
Our observations of reduced β-cell number due to apoptosis
may be consistent with dysfunctional β-cells. To test this
possibility, we turned to cultured mammalian β-cells and asked
whether suppression of Zranb3 impacts function. Upon transfec-
tion of siRNA speciﬁcally targeting murine Zranb3 (Fig. 6), we
treated MIN6 β-cells with low- or high-glucose conditions and
quantiﬁed total insulin secreted into the culture media after 1 h.
We found that, whereas control cells exhibited a marked increase
Insulin
DAPI
Control
p.L195Vfs221X
p.L195Vfs207X
25 μm
ins:mCherry
DAPI
c Control
Glucagon
Insulin
DAPI
p.L195Vfs221X
a p.L195Vfs207X on Tg(ins:mCherry ) background
5′
5′
3′
3′
3′
3′
5′
5′
p.L195Vfs221X on wild type backgroundb
d
Control
Fig. 3 Generation of zranb3 genomic zebraﬁsh mutants. a, b Identiﬁed mutations found in homozygous F2 animals by CRISPR/Cas9 in Tg(ins:mCherry) or
wild-type animals. In both lines genomic DNA deletions in exon 4 resulted in frame shift and premature stop codons (red box), conﬁrmed by sequencing.
c Confocal microscopy images of ins:mCherry transgene (red) in principal islets of wild type or mutant 5 dpf larvae. d Confocal images of whole-mount
immunostained islets of wild type or mutant 5 dpf larvae, using antibodies against insulin (red) or glucagon (green). Scale bars= 25 µM
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in insulin secretion upon treatment with high-glucose media, cells
transfected with siZranb3 did not increase the amount of insulin
secreted over the basal amount secreted in low-glucose media
(Fig. 6). These observations suggest a necessary role for Zranb3 in
β-cell functional response to high-glucose conditions.
Integrative analysis of GWAS with transcriptomic data. Inte-
grative analysis that combines GWAS summary statistics with
eQTL data were performed to identify potential new candidate
genes. The most signiﬁcant genes are shown in Fig. 7. Most of
these genes have not been reported as T2D-risk loci except for
MARCH1 which associated with T2D14. LIPC which is associated
with closely related phenotypes, including the metabolic syn-
drome15, and circulating levels of total cholesterol, HDL-
cholesterol and triglycerides in multiple studies16–22.
Discussion
The vast diversity of genetic characteristics and environments
across the world indicates that common complex disorders such
as T2D need to be studied in diverse global populations. Nowhere
is this truer than in sub-Saharan Africa, which is not only the
cradle of humanity but is also home to a vast diversity of
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populations with widely divergent lifestyle, behavioral and
environmental factors including long term exposure to pathogens
that have shaped the genomic architecture of African peoples. In
the present study, we report a genome-wide analysis of T2D in
over 5000 sub-Saharan Africans from a single diabetes association
study conducted on the continent. Reassuringly, TCF7L2
rs7903146 was genome-wide signiﬁcant as expected from pre-
vious T2D studies in Africa4,23–28, and consistent with the ﬁnd-
ings of most populations studied around the world. We also
replicated several previously reported T2D loci. Using exact
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replication strategies (same SNP, consistent direction of effect, p
value < 0.05), we demonstrated that 15% of the reported loci were
signiﬁcantly associated in this study of sub-Saharan Africans.
This is consistent with our estimates of the power of our study to
replicate known loci considering effect allele frequencies and
reported effect sizes. Using local replication strategies, which help
to identify signiﬁcant loci which would otherwise have been
missed because of allele frequency and/or LD differences between
populations, we replicated additional sixteen loci (i.e., signiﬁcant
p value in a SNP in LD with the original reported SNP). These
ﬁndings extend our previous studies of transferability of T2D loci
in sub-Sharan Africa4. Notably, the present study’s exact repli-
cation rate of 15% is marginally more than the 11% that we
previously reported in a smaller sample from the same study.
While this difference is not statistically signiﬁcant (p= 0.369, test
of difference between proportions), it suggests that larger sample
sizes may lead to increased numbers of replicated variants
because of increased statistical power. It should be noted that
transferability of reported T2D genome-wide signiﬁcant variants
between populations has always been demonstrable for a rela-
tively small fraction of all such loci, especially with African
ancestry populations13,29. Perhaps this is not unexpected given
that transferability is affected by several factors, including sample
sizes, effect allele frequencies, LD structure, and genetic archi-
tecture of the trait. While acknowledging that increased sample
size is just one of these variables, an appreciation of the ﬁnal set of
consistently replicable variants across populations will probably
become possible when sample sizes (and the resultant statistical
power) in non-European studies begin to approach those of
European GWAS.
A notable ﬁnding in the present study is the identiﬁcation of a
previously unidentiﬁed locus for T2D, namely ZRANB3 (Zinc
Finger RANBP2-Type Containing 3). Two intronic SNPs in the
gene were genome-wide signiﬁcant and the direction of effect was
consistent for the top four SNPs in a South African Zulu sample
with the meta-analysis p values of the two SNPs remaining
genome-wide signiﬁcant. The SNPs are African-speciﬁc and were
discovered by sequencing of African genomes in the African
Genome Resources Haplotype Reference Panel. Our functional
annotation of the ZRANB3 locus identiﬁed several cis- and trans-
eQTLs, indicating that the locus contains multiple functional
variants. Of relevance to T2D is our ﬁndings of two known-T2D
associated genes associated with cis-eQTLs (MCM6, DARS) and
four with trans-eQTLs (DGKB, GTF3AP5-AGMO, IL23R/
IL12RB2, SLC44A4). The DGKB/GTF3AP5-AGMO region has the
most annotation to GWAS hits with variants in the genes
showing genome-wide signiﬁcant associations with T2D30,31,
fasting plasma glucose (FPG) traits32–34 and glycated hemoglo-
bin35. IL23R/IL12RB2 is a known GWAS locus for age of onset of
T2D36, while variants in SLC44A4 have been implicated in the
interaction between T2D and iron status biomarkers37. Variants
in MCM6 and DARS were recently shown to be associated with
total cholesterol change in response to fenoﬁbrate in statin-
treated T2D38.
Our functional assays in zebraﬁsh focused on the role of the
ZRANB3 ortholog in the pancreas, one of the key tissues in T2D.
RNA-seq expression datasets of isolated β-cells showed expres-
sion of zranb3 in the principal zebraﬁsh pancreatic islet.
Knockdown of the gene led to reduced zranb3 expression and to
reduction in pancreatic β-cell number in the developing organ-
ism, which we conﬁrmed in progeny of animals having nonsense
mutations introduced into zranb3 by CRISPR. These observations
are consistent with recent evidence suggesting that Zranb3 is
highly expressed in replicating murine β-cells39, suggesting a
likely critical role of the gene in production or maintenance of β-
cells. The reduction in zebraﬁsh β-cell mass that we observed was
shown to be due to a reproducible increase in apoptosis present in
islets of animals with zranb3 knockdown. The effect of zranb3
deﬁciency in the pancreas seems to be speciﬁc to β-cells as glu-
cagon in islets is similar between knockout/knockdown and wild-
type zebraﬁsh. Glucose tolerance/uptake studied in the animals
did not show a defect in glucose uptake that would indicate
changes in insulin sensitivity or glucose disposal. We also found
that Zranb3 knockdown in a mammalian cell line (MIN6 β-cells)
resulted in an impairment of secretion of insulin in response to
high glucose. Overall, the ﬁndings from these experiments sup-
port an important role for ZRANB3 in T2D that is mediated
through a mechanism of impaired insulin response at the level of
maintenance and function of β-cell mass. These ﬁndings in
combination with the eQTL ﬁndings suggest that the ZRANB3
locus may act directly, through other loci that it regulates (e.g.,
DGKB, GTF3AP5-AGMO, and IL23R/IL12RB2) or in combina-
tion with those loci to produce the pathophysiological changes
that lead to altered glucose metabolism and T2D.
Integrative analysis of GWAS and transcriptomic studies are
increasingly being utilized to identify novel candidate genes
which may not have been detected through either type of study
alone as illustrated by loci above the null line and towards the
upper right quadrant of Fig. 7b. We utilized this approach to
generate new leads for further studies. We found some candidate
genes of which two (MARCH1 and LIPC) are established T2D-
related loci. The fact that they were not signiﬁcant in our study
indicates that integrative analysis can boost the capacity of a
GWAS to identify and/or prioritize loci for further study. One of
the major drawbacks of this type of integrative analysis is the
relatively small sample sizes of most transcriptomic datasets40,
which limits the power of the eQTL studies. However, this lim-
itation would gradually diminish as more data are generated.
The identiﬁcation of a previously unidentiﬁed candidate T2D
locus in the present study provides further support for the notion
that genome analysis studies in diverse global populations have
the potential to discover novel risk loci and improve our
knowledge of the genetic architecture of many common complex
disorders41–45. For T2D, this has been demonstrated in studies
which identiﬁed SLC6A11 in Mexicans by the SIGMA Type 2
Diabetes Consortium46, SGCG in Punjabi Sikhs47, and KCNQ1 in
East Asians48,49 as novel risk loci for T2D. In the search for novel
loci, this strategy of including populations of different ancestries
complements the strategy of increasing sample sizes to boost
statistical power to detect small effect sizes.
The present study addressed discovery science in the context of
under-represented populations in genomic research, partly in
response to the lack of diversity and predominance of European
ancestry populations in genomic studies42,44,50–52. Several
examples now exist for how lack of diversity in genomic studies is
resulting in missed opportunities for discoveries and for more
robust understanding of heterogeneity in effect sizes across ethnic
groups. A recent example from the Population Architecture using
Genomics and Epidemiology study demonstrated that one-
quarter of genetic associations in the NHGR-EBI GWAS Cata-
log show signiﬁcant heterogeneity in effects sizes between eth-
nicities53. Given that effect sizes are estimates of risk, this implies
that risk prediction would vary substantially depending on the
ethnic group. It is important to recognize that the effects of this
lack of diversity extend beyond discovery science to translational
studies because the resulting gaps in knowledge may lead to
missed opportunities for developing clinical guidelines, better
tailoring of clinical guidelines and treatment protocols and
developing new therapeutic agents45,54. Highlighting these issues
further is the recent call for better calibration of polygenetic risk
scores (PRS) to enhance transethnic utility with the hope of not
exacerbating already unacceptable health disparities as PRS is
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used to identify high-risk individuals for early intervention in
clinical and public health settings55,56.
The strengths of the present study include a relatively large
sample size, a focus on an understudied ancestral group, use of
state-of-the-art SNP microarrays and imputation to an African
enriched reference panel providing an unparalleled comprehen-
sive opportunity to test millions of common SNPs across African
genomes. A potential limitation is that SNPs with small effect
sizes are not detectable with the present sample size. More studies
in Africans and combined analysis using meta-analytic proce-
dures would overcome this limitation.
In summary, this GWAS of T2D in over 5000 sub-Saharan
Africans replicated several known T2D loci, including TCF7L2
and identiﬁed ZRANB3 as a T2D locus. Functional experiments
in zebraﬁsh suggest that ZRANB3 is important in β-cell mass, and
thereby the capacity of the pancreas to respond to insulinogenic
stimuli.
Methods
Ethics statement. All human research was conducted according to the Declaration
of Helsinki and all relevant ethical regulations for work with human participants.
The study protocol was approved by the institutional ethics review board (IRB) of
the National Institutes of Health/National Human Genome Research Institute
(protocol HG-09-N070) and the IRBs of each participating institution, including
University of Lagos, Lagos, Nigeria; College of Medicine, University of Ibadan,
Ibadan, Nigeria; University of Nigeria Teaching Hospital, Enugu, Nigeria; Uni-
versity of Science and Technology, Kumasi, Ghana; University of Ghana Medical
School, Accra, Ghana. Written informed consent was obtained from each parti-
cipant prior to enrollment.
All experiments performed on animals have been approved by the University of
Maryland Baltimore IACUC under protocol approval number 1218020.
Study participants. Study participants are from the Africa America Diabetes
mellitus (AADM) study3,6. This is a study of the genetic epidemiology of T2D in
Africa that enrolled participants from Nigeria, Ghana, and Kenya. The study
eligibility criteria and enrollment procedures have been described in detail
elsewhere3,4,6. Brieﬂy, participants were Africans enrolled through major medical
centers in Nigeria (Ibadan, Lagos, and Enugu), Ghana (Accra and Kumasi), and
Kenya (Eldoret). The most common ethnolinguistic groups in the study sample
were Yoruba and Igbo (Nigeria); Akan and Gaa-Adangbe (Ghana); and Luhya,
Kikuyu, and Kalenjin (Kenya). Participants identiﬁed at each center were ﬁrst
consented for the study and underwent the same enrollment procedures, which
included collection of demographic details, medical history, and clinical exam-
ination. Clinic procedures included anthropometry for weight, height, waist cir-
cumference, and hip circumference; three blood pressure measurements in the
sitting position; and collection of fasting blood samples. Weight and height were
measured in light clothes. Weight was measured to the nearest 0.1 kg using an
electronic scale while height was measured to the nearest 0.1 cm with a clinical
stadiometer. BMI was calculated using the formula: weight (kg)/height2 (m).
The case deﬁnition of T2D was done using the criteria of the American Diabetes
Association (ADA). The criteria were a FPG concentration ≥ 7.0 mmol/L (126 mg/
dl) or an oral glucose tolerance test (OGTT) 2 h postglucose load ≥ 11.1 mmol/L
(200 mg/dl) on more than one occasion. A diagnosis of T2D was also accepted if a
patient was on physician prescribed pharmacological treatment for T2D and a
review of clinical records showed that pre-treatment fasting glucose and/or OGTT
criteria was consistent with the diagnosis. To exclude probable cases of type 1
diabetes, patients with autoantibodies to glutamic acid decarboxylase and/or a
fasting C-peptide ≤ 0.03 nmol/L were excluded. T2D controls were required to
meet the following criteria: FPG < 6.1 mmol/L (110 mg/dl) or OGTT 2 h
postglucose load < 7.8 mmol/L (140 mg/dl) and must have none of the classical
symptoms of diabetes (polyuria, polydipsia, and unexplained weight loss).
Genotyping and imputation. The 5231 samples were genotyped on two platforms:
1808 samples were genotyped using both the Affymetrix Axiom® PANAFR SNP
array (an array with ~2.1 million SNPs that is optimized for African ancestry
populations (see Web Resources)) and the Affymetrix 319(R) Exome Array and
3423 samples were genotyped using the Illumina Consortium array: Multi-Ethnic
Global Array (MEGA) (see Web Resources). Each of the resulting datasets
underwent separate quality control. After technical quality control, sample-level
genotype call rate was at least 0.95 for all subjects. Each SNP dataset was ﬁltered for
missingness, Hardy–Weinberg equilibrium (HWE) and allele frequency. SNP
passing the following ﬁlters were retained: missingness < 0.05, HWE p < 1 × 10−6
and minor allele frequency > 0.01. SNPs that passed quality control were used as
the basis for imputation. Imputation of all samples was performed using the
African Genome Resources Haplotype Reference Panel (a new African genome
reference panel based on 4956 samples from all African and non-African 1000
Genomes Phase 3 populations and additional African genomes from Uganda,
Ethiopia, Egypt, Namibia, and South Africa) using the Sanger Imputation Service
(see Web Resources). The additional African genomes included 2298 African
samples with whole-genome sequence data from the African Genome Variation
Project (AGVP)57 and the Uganda 2000 Genomes Project (UG2G). This new panel
both increased the number of imputed variants and improved the information
score and imputation accuracy for African populations when compared with the
1000 Genomes Phase 3 Version 5 reference panel. The resulting imputation dataset
of all samples was ﬁltered for variants with MAF ≥ 0.01 and information score
(info) ≥ 0.3 for association analysis.
Association analysis. Association analysis was done using the generalized linear
mixed model association test (GMMAT) R package58, a software package for
association tests based on generalized linear mixed models. We computed PCs
using an LD-pruned subset of SNPs (Supplementary Fig. 1). Similar to our previous
study4, we found that the ﬁrst three PCs were signiﬁcant and were therefore
included in downstream analyses. To account for relatedness between individuals
in the sample, we computed a genetic relatedness matrix (GRM) using the
Genome-wide Efﬁcient Mixed Model Association algorithm59. Association testing
for T2D was done using the mixed logistic model as implemented in GMMAT.
This is a score test which was done with the imputed genotype dosages with age,
gender, BMI, the GRM and the ﬁrst three PCs as covariates.
Statistical power estimates. The power of the study for discovery was estimated
using Quanto60 and assuming an α of 5 × 10−8. For a variant with a minor allele
frequency (MAF) of 0.05, the study has 80% power to detect a genetic risk ratio
(GRR) of 1.7 and 94% power to detect a GRR of 1.8. For a variant with MAF of
0.10, the study has 82% power to detect a GRR of 1.5 and 98% power to detect a
GRR of 1.6.
Replication of ZRANB3 in an African ancestry study. To evaluate replication of
ZRANB3 in another African population, we examined the signiﬁcant variants in
South African Zulu T2D cases and controls from the Durban Diabetes Study
(DDS) and the Durban Diabetes Case–Control Study (DCC). The DDS is a
population-based cross-sectional study of nonpregnant urban black African indi-
viduals aged 18 years and above living in the city of Durban, South Africa61,62.
They all belonged to the Zulu ethnolinguistic group and a diagnosis of T2D was
based on WHO criteria. Participants in the DCC consisted of South African Zulu
patients who were diagnosed with type 2 diabetes based on WHO criteria and were
attending a diabetes clinic at either Inkosi Albert Luthuli Central Hospital in
Durban, South Africa, or one of three peripheral clinics. A total of 2578 Zulu
participants (1602 T2D cases and 976 controls) were included in the
replication study.
eQTL annotation of ZRANB3. For eQTL annotation of the genome-wide sig-
niﬁcant ZRANB3 SNPs, we utilized data from the FHS eQTL Study40 accessed via
the NCBI Molecular QTL Browser (see Web Resources). This is a microarray-based
genome-wide study that analyzed both cis- and trans-eQTLs in whole blood
samples from over 5000 study participants. We chose this database because till date
it is currently the largest, single site study of both cis-eQTLs and trans-eQTLs. First,
we used the haplotype block deﬁnition method of Gabriel et al.63 to construct
haplotypes around the two genome-wide signiﬁcant SNPs, resulting in an 18.7 kb
haplotype block around 2:136064024 and a 16.8 kb haplotype bock around
2:136019729. Next, we retrieved signiﬁcant eQTLs in these two haplotype blocks
from the FHS-eQTL Study and identiﬁed cis- as well as trans-eQTL SNP-gene
pairs. We then overlaid the gene lists from the retrieved eQTL data on the list of
signiﬁcant associations with T2D in the NHGRI-EBI GWAS Catalog. To provide
ﬁner resolution, we annotated the SNPs ﬂanking each genome-wide signiﬁcant
ZRANB3 SNP for eQTLs.
Meta-analysis. Given the paucity of genome-wide data on Africans characterized
for T2D, we conduct a meta-analysis of our GWAS with an African ancestry
dataset: a GWAS of African American samples for T2D (n= 8599) conducted on
African American participants from ﬁve studies (ARIC, the CFS, the HUFS, JHS,
and MESA) retrieved under controlled access from dbGAP. We used a ﬁxed effects
model with inverse weighting of effect sizes as implemented in METAL64 with
double genome inﬂation correction. As a check, we utilized a meta-analysis method
that allows for heterogeneity of effects as implemented in MetaSoft65 and obtained
essentially the same ﬁndings (thus, results from METAL are presented). For
transethnic meta-analysis, we conduct a meta-analysis for T2D with data from the
present GWAS, the African American studies and the DIAGRAM meta-analysis of
13 cohorts imputed from the GoT2D integrated haplotype reference panel8.
Transferability of established type 2 diabetes loci. We looked for evidence of
transferability of established T2D loci reported in the literature and curated with
the aid of the NHGRI-EBI GWAS Catalog and updated with the latest meta-
analysis studies. We considered a p value < 0.05 associated with a SNP with the
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same direction of effect as evidence of transferability. Where the exact SNP was not
present or did not show signiﬁcant association in our dataset, we examined all
SNPs with LD r2 > 0.3 and within +250 kb of the reported index SNP for asso-
ciation with T2D. Nominal association p values were adjusted for the total number
of SNPs within the region using the method of effective degrees of freedom66,67. A
locus was considered to show local replication if it had at least one of the tested
SNPs with adjusted association p value < 0.05.
Zebraﬁsh lines. Experiments were carried out using Tg(insa:mCherry)68 or wild-
type animals of the Tubingen strain. Adult zebraﬁsh were housed and naturally
mated according to standard protocol. All zebraﬁsh work was conducted in
accordance with University of Maryland IACUC guidelines.
MO and CRISPR/Cas9. MO antisense oligonucleotides (MOs) that block splicing
(SB) at the splice junction of exon 4 of zranb3 mRNA were injected into one- to
two-cell stage embryos. We designed SB MO (5′-GATACTCCTGCAAAGCAA
ACAAACA-3′). A control nonspeciﬁc MO was used (5′-CCTCTTACCTCAGTTA
CAATTTATA-3′). The embryos were grown at 28 °C until harvesting for analyses.
MO efﬁcacy and off-target toxicity was assessed in cDNA generated from total
RNA isolated from homogenates of whole 5 days postfertilization (dpf) larvae and
qPCR analysis11.
Target sites for CRISPR were determined and designed according to published
protocols11. We identiﬁed target sites within either exon 4 or exon 7 of zranb3 to
which we generated sgRNAs by in vitro transcription using the following oligo
sequences:
Exon 4 oligo1: TAATACGACTCACTATAGGATGGCACGCTTGGCGCTCG
TTTTAGAGCTAGAAATAGC
Exon 7 oligo 1: TAATACGACTCACTATAGGGAATTCGCTGGCGTATTTG
TTTTAGAGCTAGAAATAGC
Universal Oligo 2: AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGAT
AACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC
The sgRNAs, at 25 pg/µl, along with Cas9 mRNA, at 300 pg/µl, were
microinjected directly into the cell during the single cell stage of embryonic
development.
Quantitative RT-PCR. Zebraﬁsh were anesthetized with MS-222, before removing
a small section of caudal ﬁn, or grinding up a 24 hpf embryo. RNA was extracted
from the sample using Trizol reagent (Life Technologies) according to manu-
facturer’s protocol and puriﬁed using the RNeasy Kit (QIAGEN). cDNA was
transcribed using the Fermentas First Strand cDNA Transcription Kit (Thermo
Scientiﬁc) according to manufacturer’s protocol, diluted to 1∶9 and added to a
reaction including target-speciﬁc primers (sequences provided in Supplementary
Note 1) and LightCycler 480 SybrGreen (Roche) and run on a LightCycler 480
(Roche) for 5 min at 95 °C then 40 cycles of 95 °C (10 s), 58 °C (10 s), 72 °C (10 s)
then 5 min at 72 °C. A reverse-transcriptase-free sample was used as a negative
control. All samples were run in duplicate with the CT value normalized to Actin,
RPIII, and/or EF1α to calculate relative expression for each gene in each sample.
Biological replicates were repeated.
Whole-mount immunoﬂuorescence, in situ hybridization, and imaging of
larval zebraﬁsh islets. Zebraﬁsh embryos were ﬁxed overnight in 4% paraf-
ormaldehyde, washed three times in PBS+ Tween20 (0.1%). Embryos were trans-
ferred to 150mM Tris pH9 for 5 min at room temperature, then 15min at 70 °C.
Embryos were then cryoprotected in 30% sucrose overnight at 4 °C and then pro-
cessed for immunoﬂuorescence or imaged using a Nikon W1 confocal microscope at
60×. Images were compiled and analyzed using Fiji69. Immunoﬂuorescent staining
was carried as per previous protocols11 using activated caspase-3 and insulin anti-
bodies or antibody against glucagon (Sigma, 2654) used at 1:100 concentration.
Zebraﬁsh β-cell analysis. The Tg (insa:mCherry) line which labels β-cells spe-
ciﬁcally by expressing mCherry under the control of the preproinsulin (insa)
promoter was used to quantify the number of β-cells according to previous pub-
lished protocol11. Brieﬂy, embryos were ﬁxed in 4% PFA, washed in phosphate
buffered saline with Tween-20 and ﬂat mounted in ProLong®Gold antifade (Life
Technologies) with the right lateral side facing the coverslip. Sufﬁcient pressure was
applied to disrupt the islets in order to visualize individual cells. The number of β-
cells was counted manually under an Olympus IX71 ﬂuorescence microscope and
imaged and analyzed using CellSens software. Quantiﬁcation was conﬁrmed in
separate experiments using whole-mount 5 dpf larvae immunostained for insulin
and imaged on the Nikon W1 confocal microscope at 60×. Images were compiled
and analyzed for depth resolution using Fiji69. The analysis of β-cells was per-
formed on embryos collected from three different injections of either control or test
morpholinos or embryos generated from mutant adults.
2-NBDG uptake. Embryos at 5 days post-fertilization (dpf) were incubated with 0,
300, 600, or 1000 μM 2-(N-(7-Nitrobenz-2oxa-1,3-diazol-4-yl)Amino)-2-Deox-
yglucose (2-NBDG, abcam), a ﬂuorescent glucose mimetic, for 6 h at 28.5 °C.
Embryos were immobilized using 3-amino benzoic acid ethyl ester (Tricaine) and
imaged on a Lionheart FX at 4× (BioTek Instruments). Total retinal ﬂuorescence
images were compiled and quantiﬁed using Fiji69.
Isolation of zebraﬁsh β-cells and cell cycle analysis. Single-cell dissociation was
carried out on Tg(insa:mCherry) embryos as per published protocols70, and stained
for DNA content using DyeCycle Violet (Life Technologies). DNA content analysis
was carried out by FACS on a BD LSR II and analyzed using the FlowJo software
package (FlowJo, LLC).
FACS-assisted Isolation and Analysis of β-cells. Five days post-fertilization larvae
were dissociated into single cells using published methodology70. For RNA-Seq ana-
lysis, the single-cell suspension was sorted via mCherry+ signal using a BD FACS Aria
II (BD BioSciences) and RNA was extracted from isolated β-cell fraction via extraction
kit (Qiagen). RNA quantity and quality were assessed via 260/280 absorption. Samples
were provided in duplicate for library preparation and quantitative analysis using Next
Generation Sequencing and an Illumina HiSeq 2 × 150 PE (GENEWIZ). Fragments
were aligned to the GRZ10 genome with CLC Genomics Server program v10.0.1. We
used three hundred 5 dpf larvae for sorting and isolated approximately 0.08% of all
cells, based on expression of the mCherry reporter gene (i.e., β-cells). In total,
1500–2000 cells were used for generation of the RNA-Seq dataset.
Cultured β-cells and glucose stimulated insulin secretion. Culture ofMIN6 cells
(CRL11506; American Type Culture Collection) were cultured in DMEM-H
(American Type Culture Collection) supplemented with 15% heat-inactivated fetal
bovine serum and 1× penicillin/streptomycin (Sigma). Knockdowns were accom-
plished using Lipofectamine 3000 (Life Technologies) and either scrambled control or
Zranb3-targeted siRNA (Life Technologies). Efﬁcacy of siRNA knockdown was
evaluated via qRT-PCR. Glucose stimulation of cultured β-cells was performed on
cells plated at equal densities, as determined by hemocytometer counts, using 2.5 and
16.7mM glucose as baseline and high-glucose concentrations, respectively. Insulin
was assessed in media collected at the indicated time points using high-sensitivity
insulin ELISA (Mercodia Mouse Insulin ELISA Catalog number 10-1247-10).
Integrative analysis of GWAS with transcriptomic data. To identify potentially
novel candidate genes and generate new hypotheses, we leveraged our GWAS to
conduct functional gene set-based analysis of the AADM GWAS summary sta-
tistics using publicly available transcriptomic data on selected T2D-related tissues.
We conducted gene-based association analysis of eQTLs with the intention of
combining genome-wide association statistics with transcriptomic data to co-
localize T2D loci which may not have been discovered by using either approach
alone. We used a gene-based method instead of a single-SNP method because
under the assumption that the expression of a gene is causally-related to disease
status and gene expression is determined by multiple independent SNPs, a gene-
based test that captures the aggregate effects of these SNPs should have better
power over testing each SNP individually. We used EUGENE v1.3b71 using the
AADM GWAS summary statistics as input and accounted for LD between variants
with the 1000 Genomes AFR data. We restricted our analyses to adipose tissue,
skeletal muscle and whole blood (T2D-related target tissues for which reference
eQTL data are available) using precomputed eQTL reference data provided by the
software authors. We used Satterthwaite’s approximation to estimate the sig-
niﬁcance of the gene-based sum statistic (i.e., GCTA-fastBAT)72, a method which is
more efﬁcient than using simulations to estimate the gene-based sum statistic and
is recommended as the default approach to estimate signiﬁcance.
Web resources. For Affymetrix Axiom® PANAFR array, see https://www.
thermoﬁsher.com/order/catalog/product/901788?ICID=search-product; for ClinVar
Accession SCV000191187.1, see https://www.ncbi.nlm.nih.gov/clinvar/variation/
156804/; for dbGaP, see https://www.ncbi.nlm.nih.gov/gap; for Eugene, see https://
genepi.qimr.edu.au/staff/manuelF/eugene/download.html; for GMMAT, see https://
content.sph.harvard.edu/xlin/software.html#gmmat; for Illumina Multi-Ethnic Global
Array (MEGA), see https://www.illumina.com/science/consortia/human-consortia/
multi-ethnic-genotyping-consortium.html; for MetaSoft, see http://genetics.cs.ucla.
edu/meta/index.html; for The NHGRI-EBI Catalog of published genome-wide asso-
ciation studies, see https://www.ebi.ac.uk/gwas/; for NCBI Molecular QTL Browser,
see https://preview.ncbi.nlm.nih.gov/gap/eqtl/studies/; for OMIM, see http://www.
omim.org/; for Sanger Imputation Service, see https://imputation.sanger.ac.uk/.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The GWAS summary statistics are available at dbGap [Accession number phs001844.v1.
p1] for disease-related research consistent with the ethical approvals governing the study.
The RNA-Seq datasets are accessible online at the Gene Expression Omnibus (GEO)
under the accession “GSE125354” [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE125354]. All other data are contained within the article and its Supplementary
Information or upon reasonable request from the corresponding author.
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